1Weir MR,Elkins M,Liss C,et al.Efficacy,tolerability and quality of life of losartan,alone or with hydrochlorothiazide,versus nifedipine GITS in patients with essential hypertension[J].Clin Ther.1996,18(3):411-428.
2Oparil S,Barr E,Elkins M,et al.Efficacy,tolerability and quality of life of losartan,alone or with hydrochlorothiazide,versus amlodipine,alone or wit hydrochlorothiazide in patients with essential hypertension[J].Clin Ther.1996,18(4):608-625.
3Goa KL,Wagstaff AJ.Losartan potassium:a review of its pharmacology,clinical efficacy and tolerability in the management of hypertension[J].Drugs.1996,51(5):820-845.
1O` Hollaren MT.Porter M: Angiotension converting enzyme inhibitors and the allergist[].Annals of Allergy Asthma Immunology.1990
2Woo KS,Nicholls MG.High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese[].British Journal of Clinical Pharmacology.1995
3Tikkanen I,Omvik P,Jensen H A.Comparison of the angiotensin Ⅱ antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension[].Journal of Hypertension.1995
4Edwards RM,Trizna W,Stack EJ.Interaction of nonpeptide angiotension Ⅱ receptopr antagonists with the urate ransporter in rat renal brush-border membranes[].Journal of Pharmacology and Experimental Therapeutics.1996
5Dahlof B,Keller SE,Makrisl L,et al.Efficacy and tolerability of losartan potassium and atenolol in patient with mild to moderate essential hypertension[].American Journal of Hypertension.1995
1Kaplan NM.The CARE Study:a postmarketing evaluation of ramipril in 11,100 patients.The Clinical Altace Real-World Efficacy (CARE) Investigators.Clin Ther,1996,18:658-670.
2The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an Angiotensin-Converting-Enzyme Inhibitor,Ramipril,on Cardiovascular Events in High-Risk Patients.NEJM,2000,342:145-153.
3Zhu JR,Bai J,Cai NS,et al.Efficacy and safety of telmisartan vs.losartan in control of mild-to-moderate hypertension:a multicentre,randomised,double-blind study.International Journal of Clinical Practice,2004,12:46-49.
4Dahlof B,Devereux R,de Faire U,et al.The losartan intervention for endpoint reduction(LIFE)in hypertension study:rationale,design,and methods.The LIFF study group.Am J Hypertens,1997, 10(7):705-713.
5Sen S,Tarazi RC,Bumpus FM.Effect of converting enzyme inhibitor(SQ14225) on myocardiol hypertrophy in spontanesusly hypertensive rats.Hypertension, 1980, 2(2):169-176.
6Weir MR,Elkins M,Liss C,et al.Efficady,tolerability and quality of life of losartan,alone or with hydrochlorothiazide,versus nifedipine GITS in patients with essential hypertension.Clin Ther, 1996, 18(3):411-428.
7Oparil S,Barr E,Elkins M,et al.Efficacy,tolerability and quality of life of losartan ,alone or with hydrochlorothiazide,versus amlodipine,alone or with hydrochlorothiazide in patients with essential hypertension.Clin Ther,1996, 18(4):608-625.
8Goa KL,Wagstaff AJ.Losartan potassium:a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs,1996, 51(5):820-845.
9Mackay JH, Arcuri KE, Goldberg AI, et al.Losartan and low-dose hydrochlorothiazide in patients with essential hypertension.Arch Intern Med, 1996, 156(3):278-285.
